ng28ÄϹ¬

ng28ÄϹ¬ÔÚÆøºò±ä¸ïºÍË®Äþ¾²ÁìÓòÈÙ»ñCDP×î¸ßÆÀ¼¶¡°A¡±¼¶

2025Äê2ÔÂ6ÈÕ£¬ng28ÄϹ¬Ðû²¼£¬ÈÙ»ñ¹ú¼Ê·ÇÓªÀû×éÖ¯CDPÐû²¼µÄ2024ÄêÆøºò±ä¸ïºÍË®Äþ¾²ÁìÓò×î¸ßÆÀ¼¶¡°A¡±¼¶ÆóÒµ³Æºô¡£1

ng28ÄϹ¬½«¡°È«ÇòÇé¿öÓѺÃÐÍÒµÎñÔ˶¯¡±È·¶¨ÎªÆä½¹µãÒéÌâÖ®Ò»¡£»ùÓÚ¡°ng28ÄϹ¬¼¯ÍÅÇé¿ö±£»¤Õþ²ß¡±£¬ng28ÄϹ¬ÕýÔÚÈ«¼¯ÍÅÄÚ»ý¼«Íƶ¯ÖصãÇé¿ö±£»¤Ô˶¯£¬°üÀ¨Æøºò±ä¸ïÓ¦¶ÔºÍ¿ÉÁ¬ÐøË®×ÊÔ´ÀûÓá£ÔÚÆøºò±ä¸ïÓ¦¶Ô·½Ã棬ng28ÄϹ¬ÖÂÁ¦ÓÚÖúÁ¦ÍÑ̼Éç»áµÄʵÏÖ£¬ÒÑÔÚ2023Äê¶ÈÈÙ»ñ¡°¿ÆÑ§Ì¼Ä¿±ê½¨Ò飨SBT£©¡±µÄSBT1.5¡ãCÄ¿±êÅú×¼£¬²¢»ý¼«¼ÓÈëÈÕ±¾Æøºò½¨Ò飨JCI£©µÄ¡°ÁãÅŷžºÈü¡±£¬¸Ã¾ºÈüÖ¼ÔÚºôÓõ¸÷½çÅäºÏŬÁ¦£¬µ½2050ÄêʵÏÖ¾»ÁãÅÅ·Å¡£2±ðµÄ£¬ÔÚ¿ÉÁ¬ÐøË®×ÊÔ´ÀûÓ÷½Ã棬ng28ÄϹ¬ÒÑÖÆ¶¨ÖÐÆÚÄ¿±ê£¬¼´µ½2030Äê¶ÈÈ«¹«Ë¾µÄÓÃË®Á¿½Ï2023Äê¶È¼õÉÙ7%3£¬²¢Í¨¹ýʵÑéÊÒ·ÏÒº½ÓÄɺÍÓêË®ÀûÓõȲ½·¥ÍƽøË®×ÊÔ´µÄ¸ßЧÀûÓá£

ÓйØng28ÄϹ¬Çé¿ö±£»¤Ô˶¯µÄ¸ü¶àÏêϸÐÅÏ¢£¬Çë²ÎÔÄng28ÄϹ¬¹ÙÍø¡£

 

ng28ÄϹ¬µÄÆóÒµÀíÄîÊǽ«»¼ÕßÀûÒæºÍÃñÖÚ½¡¿µ·ÅÔÚÊ×룬Âú×ãÆä¶àÑù»¯ÐèÇó£¬ÎªÌáÉýÆä¸£ìí×ö³öТ¾´¡£ÎªÁËʵÏÖ¡°ÌåÌùÈËÀཡ¿µ¡±£¨hhc£©ÕâÒ»ÀíÄÊ×ÏÈҪȷ±£È«ÇòÇé¿öµÄ¿ÉÁ¬ÐøÐÔÉú³¤£¬ÕâÊÇÆäÒµÎñÔ˶¯µÄ»ù´¡¡£ng28ÄϹ¬½«¼ÌÐøÎȲ½Íƽø¼õ»ºÆøºò±ä¸ïµÄ¾Ù´ë£¬Í¨¹ýÈ·±£¿ÉÁ¬ÐøÐÔÉç»áÉú³¤£¬ÖúÁ¦ÈËÃÇ¡°»ñµÃ×î³ä·ÖµÄÈËÉú¡±¡£

 

  1. ×ܲ¿Î»ÓÚÓ¢¹úµÄ·ÇÓªÀû×éÖ¯¡£¸Ã×éÖ¯ÔËÓª×ÅÈ«ÇòΨһµÄ¶ÀÁ¢Çé¿öÐÅÏ¢Åû¶ϵͳ¡£
  2. ÏêÇéÇë²ÎÔÄÒÔÏÂÐÂΟ壺¡¶2050ÄêʵÏÖ¾»ÁãÅÅ·Å£ºÔöÇ¿ÎÂÊÒÆøÌå¼õÅžٴ롷£¨https://www.eisai.com/news/2024/news202412.html£©
  3. °´µ¥Î»ÏúÊÛ¶îÅÌËã

 

ýÌåÁªÂ磺

ng28ÄϹ¬Öêʽ»áÉç

¹«¹²¹ØÏµ²¿

µç»°£º+81-(0)3-3817-5120

 

±àºÅ£ºECN-2025-0014

ÃÀ¹úʳƷҩƷ¼à¶½ÖÎÀí¾Ö£¨FDA£©Åú×¼ÂØ¿¨Ä¹£¨Ó¢ÎÄÉÌÆ·Ãû£ºLEQEMBI?ÖÐÎÄÉÌÆ·Ãû£ºÀÖÒâ±£?£©¾²Âö×¢É䣨IV£©Î¬³Ö¼ÁÁ¿ÓÃÓÚÖÎÁÆÔçÆÚ°¢¶û´Äº£Ä¬²¡

  • ÿËÄÖÜÒ»´ÎµÄά³Ö¼ÁÁ¿ÖÎÁÆ¿ÉÄܸü±ãÓÚ»¼ÕߺÍÕÕ»¤Õß¼ÌÐø°¢¶û´Äº£Ä¬²¡µÄÖÎÁÆ£»
  • °ß¿éÇå³ýºó£¬°¢¶û´Äº£Ä¬²¡µÄ½øÕ¹²¢²»»áÍ£Ö¹£»
  • Á¬ÐøÊ¹ÓÃLEQEMBIÖÎÁÆ¿ÉÒÔ¼õ»º¼²²¡½øÕ¹£¬²¢ÑÓ³¤ÖÎÁÆÐ§Òæ¡£

 

ng28ÄϹ¬ºÍ²³½¡Ðû²¼£¬ÃÀ¹úʳƷҩƷ¼à¶½ÖÎÀí¾Ö£¨FDA£©ÒÑÅú×¼ÂØ¿¨Ä¹£¨ÃÀ¹úÉÌÆ·Ãû£ºLEQEMBI?£¬ÖÐÎÄÉÌÆ·Ãû£ºÀÖÒâ±£?£©Ã¿ËÄÖÜÒ»´ÎµÄ¾²Âö×¢É䣨IV£©Î¬³Ö¼ÁÁ¿¸øÒ©µÄÔö²¹ÉúÎïÖÆÆ·Ðí¿ÉÉêÇ루sBLA£©¡£ÂØ¿¨Ä¹ÓÃÓÚÖÎÁư¢¶û´Äº£Ä¬²¡£¨AD£©ÒýÆðµÄÇá¶ÈÈÏÖªÕϰ­ºÍÇá¶È°¢¶û´Äº£Ä¬²¡£¨Í³³ÆÎªÔçÆÚAD£©¡£ÔÚÍê³É18¸öÔ¡¢Ã¿Á½ÖÜÒ»´ÎµÄÆðʼ½×¶ÎÖÎÁƺ󣬿ɿ¼ÂÇת»»ÎªÃ¿ËÄÖÜÒ»´Î¡¢10 mg/kgµÄά³Ö¼ÁÁ¿¸øÒ©¼Æ»®£¬»ò¼ÌÐøÃ¿Á½ÖÜÒ»´Î¡¢10 mg/kgµÄ¸øÒ©¼Æ»®¡£

 

¸ÃÔö²¹ÉúÎïÖÆÆ·Ðí¿ÉÉêÇ루sBLA£©»ùÓÚ¶ÔIIÆÚÑо¿£¨Ñо¿201£©¼°Æäºã¾ÃÀ©Õ¹£¨LTE£©Ñо¿£¬ÒÔ¼°Clarity ADÑо¿£¨Ñо¿301£©¼°ÆäLTEÑо¿µÄÊÓ²ìÊý¾Ý½øÐн¨Ä£ÆÊÎö¡£Ä£ÐÍÄ£ÄâÔ¤²â£¬ÔÚÍê³É18¸öÔ¡¢Ã¿Á½ÖÜÒ»´ÎµÄÆðʼ½×¶ÎÖÎÁƺ󣬿ɿ¼ÂÇת»»ÎªÃ¿ËÄÖÜÒ»´Î¡¢10?mg/kgµÄά³Ö¼ÁÁ¿¸øÒ©¼Æ»®£¬»ò¼ÌÐøÃ¿Á½ÖÜÒ»´Î¡¢10?mg/kgµÄ¸øÒ©¼Æ»®£¬½«Äܹ»¼á³ÖÖÎÁƵÄÁÙ´²ºÍÉúÎï±ê¼ÇÎï·½ÃæµÄÒæ´¦¡£°¢¶û´Äº£Ä¬²¡£¨AD£©ÊÇÒ»¸öÁ¬Ðø½øÐеÄÉñ¾­¶¾ÐÔÀú³Ì£¬Ê¼ÓÚ°ß¿é³Á»ý֮ǰ£¬²¢ÔÚÆäºó¼ÌÐøÉú³¤1,2,3¡£ÂØ¿¨Ä¹Í¨¹ýÁ¬ÐøÇå³ýÔ­ÏËάºÍ¿ìËÙÇå³ý°ß¿é¶Ô¿¹AD¡£Í¨¹ýÁ¬Ðø¸øÒ©£¬ÂØ¿¨Ä¹¿ÉÇå³ý¸ß¶¾ÐÔÔ­ÏËά£¬×ÝÈ»A¦Â°ß¿éÒÑ´Ó´óÄÔÖÐÇå³ý£¬Ô­ÏËάÈÔ»á¼ÌÐø¶ÔÉñ¾­ÔªÔì³ÉËðÉË¡£

 

ÂØ¿¨Ä¹ÒÑÔÚÃÀ¹ú¡¢ÈÕ±¾¡¢Öйú¡¢º«¹ú¡¢ÖйúÏã¸Û¡¢ÒÔÉ«ÁС¢°¢ÁªÇõ¡¢Ó¢¹ú¡¢Ä«Î÷¸çºÍÖйú°ÄÃŵȹú¼ÒºÍµØÇø»ñµÃÅú×¼¡£2024Äê11Ô£¬Å·ÖÞÒ©Æ·ÖÎÀí¾Ö£¨EMA£©ÏÂÊôµÄÈËÓÃҩƷίԱ»á£¨CHMP£©¶Ô¸ÃÖÎÁÆÒ©Îï¸øÓèÁË»ý¼«Òâ¼û£¬½¨ÒéÓèÒÔÅú×¼¡£ng28ÄϹ¬ÒÑÔÚ17¸ö¹ú¼ÒºÍµØÇøÌá½»ÁËÂØ¿¨Ä¹µÄÉÏÊÐÉêÇë¡£±ðµÄ£¬2025Äê1Ô£¬ÃÀ¹úʳƷҩƷ¼à¶½ÖÎÀí¾Ö£¨FDA£©ÒÑÊÜÀíng28ÄϹ¬Ìá½»µÄÂØ¿¨Ä¹Æ¤ÏÂ×Ô¶¯×¢ÉäÿÖÜά³Ö¼ÁÁ¿¸øÒ©µÄÔö²¹ÉúÎïÖÆÆ·Ðí¿É£¨BLA£©ÉêÇ룬²¢½«¡¶´¦·½Ò©Óû§Óöȷ¨°¸¡·£¨PDUFA£©Ðж¯ÈÕÆÚ¶¨Îª2025Äê8ÔÂ31ÈÕ¡£

 

ÂØ¿¨Ä¹µÄÈ«Çò¿ª·¢ºÍ×¢²áÉêÇëÓÉng28ÄϹ¬Ö÷µ¼£¬¶ø²úÆ·ÔòÓÉng28ÄϹ¬ºÍ²³½¡ÅäºÏÉÌÒµ»¯ºÍÍÆ¹ã¡£ÆäÖУ¬ng28ÄϹ¬ÓµÓÐ×îÖÕ¾ö²ßȨ¡£

 

ýÌåÁªÏµ

Eisai Co., Ltd.

Public Relations Department

TEL: +81 (0)3-3817-5120

 

Eisai Inc. (U.S.)

Julie Edelman

1-862-213-5915

Julie_Edelman@eisai.com

 

Eisai Europe, Ltd.

EMEA Communications Department

+44 (0) 786 601 1272

Emea-comms@eisai.net

 

Biogen Inc.

Jack Cox

+ 1-781-464-3260

public.affairs@biogen.com

 

Ͷ×ÊÕßÁªÏµ

Eisai Co., Ltd.

Investor Relations Department

TEL: +81 (0) 3-3817-5122

 

Biogen Inc.

Tim Power

+1-781-464-2442

IR@biogen.com

 

 

²Î¿¼×ÊÁÏ£º

  1. LEQEMBI (lecanemab-irmb) injection, for intravenous use [package insert]. Nutley, NJ: Eisai Inc.
  2. Iwatsubo T, Irizarry M, van Dyck C, Sabbagh M, Bateman RJ, Cohen S. Clarity AD: a phase 3 placebo-controlled, double-blind, parallel-group, 18-month study evaluating lecanemab in early Alzheimer¡¯s disease. Presented at: CTAD Conference; November 29-December 2, 2022; San Francisco, CA.
  3. Hampel H, Hardy J, Blennow K, et al. The amyloid-¦Â pathway in Alzheimer¡¯s disease. Mol Psychiatry. 2021;26(10):5481-5503.

 

±àºÅ£ºECN-2025-0012

ng28ÄϹ¬½«ÎªÊ³Æ·ÆóÒµÌṩ½µµÍÈÏ֪˥ÍËΣº¦ÓëÓªÑøÖ¸µ¼ÒÔ¼°ÍâÂô/²Í°ü¿ª·¢Ö¸ÄÏ

ÈÕ±¾¹úÁ¢³¤ÊÙÒ½ÁÆÑо¿ÖÐÐÄ£¨NCGG£©Óëng28ÄϹ¬Ðû²¼£¬ÔÚ¹úÁ¢³¤ÊÙÒ½ÁÆÑо¿ÖÐÐĵÄÖ¸µ¼Ï£¬ng28ÄϹ¬Öƶ¨ÁË¡¶½µµÍÈÏ֪˥ÍËΣº¦ÓëÓªÑøÖ¸ÄÏ¡·£¨ÒÔϼò³Æ¡°Ö¸ÄÏ¡±£©ºÍ¡¶ÓÐÖúÓÚ½µµÍÈÏ֪˥ÍËΣº¦µÄÍâÂô/²Í°üÊֲᡷ£¨ÒÔϼò³Æ¡°Êֲᡱ£©£¬²¢¿ªÊ¼Ïò°üÀ¨ÍâÂô/²Í°üЧÀÍÔÚÄÚµÄʳƷÏà¹ØÆóÒµÌṩ¡£

ÄϹ¬NG28(Öйú)¹Ù·½ÍøÕ¾-µÇ¼Èë¿Ú

ÖÚËùÖÜÖª£¬½¡¿µµÄÒûʳÔÚÉú³¤¡¢·¢ÓýÒÔ¼°¼²²¡Ô¤·ÀµÈ·½Ãæ·¢»Ó×ÅÖÁ¹ØÖØÒªµÄ×÷Ó᣽üÄêÀ´£¬Óб¨µÀ³Æ£¬½¡¿µÒûʳÔÚÔ¤·À³Õ´ôÖ¢ºÍÇá¶ÈÈÏÖªÕϰ­£¨MCI£©·½ÃæÒ²¾ßÓÐDZÔÚÒæ´¦¡£Ëæ×ÅÈËÃǶÔÈÏÖª¹¦Ð§Ë¥ÍËÔçÆÚ·¢Ã÷ºÍ¸ÉÔ¤ÖØÒªÐÔµÄÈÏʶÈÕÒæÔöÇ¿£¬Êʵ±µÄÒûʳÒѱ»ÊÓΪ½µµÍ³Õ´ô֢Σº¦µÄÒªº¦ÒòËØ¡£

¹úÁ¢³¤ÊÙÒ½ÁÆÑо¿ÖÐÐÄÖÂÁ¦ÓÚÐû²¼Ñо¿½á¹û£¬ÕâЩ½á¹ûÓÐÖúÓÚά³ÖÈÏÖª¹¦Ð§²¢¸ÄÉÆÃñÖÚÓªÑø×´¿ö£¬Í¬Ê±»ý¼«Íƶ¯ÕâЩ½á¹ûÔÚÉç»áÖеÄʵ¼ÊÓ¦Óá£ng28ÄϹ¬Æ¾½èÆäÔÚ³Õ´ôÖ¢ÁìÓò40ÄêµÄÑо¿¿ª·¢¾­Ñ飬ͨ¹ýÓë¸÷·½ÏàÖúͬ°éµÄ½ôÃÜЭ×÷£¬ÖÂÁ¦ÓÚΪ½â¾ö³Õ´ôÖ¢Ïà¹ØÎÊÌâ×ö³ö»ý¼«Ð¢¾´¡£´Ë´Î£¬ÔÚ¹úÁ¢³¤ÊÙÒ½ÁÆÑо¿ÖÐÐĵÄÖ¸µ¼Ï£¬ng28ÄϹ¬¹«Ë¾Éó²éÁË8,269ÏÄÚÍâ¹ØÓÚ½µµÍÈÏ֪˥ÍËΣº¦µÄÓªÑøºÍÒûʳÏà¹ØÑо¿£¬²¢»ùÓÚÕâЩÑо¿½á¹ûÖÆ¶¨ÁË¿ÉÄܽµµÍÈÏ֪˥ÍËΣº¦µÄÒûʳÀàÐÍÖ¸ÄÏ¡£±ðµÄ£¬ng28ÄϹ¬»¹¶ÔÓëά³ÖºÍ¸ÄÉÆÈÏÖª¹¦Ð§Ïà¹ØµÄÖ¤¾Ý½øÐÐÁË¿Í¹ÛÆÀ¹À£¬²¢´Ó¡°Ô¤·Àµ¼ÖÂÈÏ֪˥Í˵ÄÓªÑø²»Á¼ºÍÐéÈõ¡±¡¢¡°ÉãÈë½µµÍÈÏ֪˥ÍËΣº¦µÄÓªÑøËØ¡±ÒÔ¼°¡°¼á³Ö½µµÍÈÏ֪˥ÍËΣº¦µÄÓªÑøÆ½ºâ¡±µÈ½Ç¶È³ö·¢£¬Öƶ¨Á˹ØÓÚ¿ª·¢ÍâÂô/²Í°ü²Ëµ¥µÄÊֲᡣ

ng28ÄϹ¬½«Æ¾¾ÝÐèÇó£¬ÏòͬÒâÖ§³Ö³Õ´ôÖ¢Ðû´«Ô˶¯µÄʳƷÏà¹ØÆóÒµÌṩËùÖÆ¶¨µÄÖ¸ÄϺÍÊֲᡣ¹úÁ¢³¤ÊÙÒ½ÁÆÑо¿ÖÐÐÄÓëng28ÄϹ¬¼Æ»®ÍØÕ¹ÓëʳƷÏà¹ØÆóÒµµÄÏàÖú¹æÄ££¬²»µ«½ö¾ÖÏÞÓÚÍâÂô/²Í°üÒµÎñ¡£ÕâÒ»¾Ù´ëÒ²ÓÐÖúÓÚÍÆ¶¯ÈÕ±¾¡¶ÍƽøÊµÏÖ¹²ÉúÉç»áµÄ³Õ´ôÖ¢»ù±¾·¨¡·ËùÌᳫµÄ³Õ´ôÖ¢ÈÝÄÉÐÔÉç»áµÄʵÏÖ¡£¹úÁ¢³¤ÊÙÒ½ÁÆÑо¿ÖÐÐÄÓëng28ÄϹ¬Ö¼ÔÚͨ¹ý¹¤Òµ½ç¡¢Õþ¸®¼°Ñ§Êõ½çµÄ½ôÃÜÏàÖú£¬ÅäºÏ¸ÄÉÆÃñÖÚÓªÑø×´¿ö£¬ÎªÑÓ³¤½¡¿µÔ¤ÆÚÊÙÃü¡¢´´Á¢Ò»¸öÈÃÀÏÄêÈËÄܹ»ÔÚÉçÇøÖж¨ÐÄÉú»îµÄÉç»áТ¾´×Ô¼ºµÄÁ¦Á¿¡£

±àºÅ£ºECN-2025-0013

ng28ÄϹ¬³öÆ·¡¶1%µÄʱ¼ä£¬¸Ä±äÊÀ½ç¡·Ðû²¼

ng28ÄϹ¬Ðû²¼£¬Æä¹«Ë¾½éÉÜÊÓÆµ¡¶1%µÄʱ¼ä£¬¸Ä±äÊÀ½ç¡·ÕýʽÐû²¼¡£ng28ÄϹ¬µÄÆóÒµÀíÄîÊǽ«»¼ÕߺÍÃñÖÚ½¡¿µ·ÅÔÚÊ×λ£¬ÎªÔö¼ÓËûÃǵĸ£ìí×ö³öТ¾´£¬´Ó¶øÂú×ãÈ«ÇòÒ½Áƽ¡¿µµÄ¶àÑù»¯ÐèÇó¡£ÎªÁËʵÏÖÕâÒ»human health care£¨hhc£©ÀíÄng28ÄϹ¬ÕýÔÚʵʩһÏî¾Ù´ë£¬¼´ÈÃÈ«ÇòÔ±¹¤Óà 1%µÄÊÂÇéʱ¼äÓ뻼ÕßÔÚÒ»Æð£¬Á˽âËûÃǵÄϲŭ°§ÀÖ£¬ÎªËûÃÇ´´Á¢¼ÛÖµ¡£¸ÃӰƬÒÔ¡°1%µÄʱ¼ä£¬¸Ä±äÊÀ½ç¡±ÎªÖ÷Ö¼£¬½éÉÜÁËng28ÄϹ¬»ùÓÚhhcÀíÄչµÄÔ˶¯¡£Ó°Æ¬ÖУ¬ng28ÄϹ¬ÈËÔÚÓ뻼ÕßÏà´¦µÄʱ¼äÖиÐÖª»¼ÕßµÄÓÇÂÇ£¬²¢ÔÚ½â¾öÕâЩÓÇÂǵÄÇ¿ÁÒÔ¸ÍûµÄÇý¶¯ÏÂÓ­½ÓÌôÕ½£¬´´Á¢Á¢Ò죬´Ó¶øÎª»¼ÕߺÍÃñÖÚµÄÉú»îÌṩ֧³Ö¡£½Ó´ýԢĿ´ËӰƬ¡£

ÄϹ¬NG28(Öйú)¹Ù·½ÍøÕ¾-µÇ¼Èë¿Ú

±àºÅ£ºECN-2025-0009

ng28ÄϹ¬µÚ¾Å´ÎÈëѡȫÇò¿ÉÁ¬ÐøÉú³¤ÆóÒµ100Ç¿

ng28ÄϹ¬ÈëÑ¡ÓɼÓÄôóýÌåºÍͶ×Ê×Éѯ¹«Ë¾Corporate Knights Inc.Ðû²¼µÄ2025ÄêÈ«Çò100¼Ò×î¿ÉÁ¬ÐøÉú³¤ÆóÒµ£¨Global 100£©£¬Î»ÁеÚ35¡£ÕâÊÇng28ÄϹ¬µÚ¾Å´ÎÉϰñ£¬ÊÇÈ«ÇòÅÅÃû×î¸ßµÄÖÆÒ©ÆóÒµ£¬Ò²ÊÇÈ«Çò100Ç¿ÖÐÅÅÃû×î¸ßµÄÈÕ±¾ÆóÒµ¡£

 

È«Çò100Ç¿°ñµ¥Ê¼ÓÚ2005Ä꣬ƾ¾ÝÆóÒµÔÚESG£¨Çé¿ö¡¢Éç»áºÍÖÎÀí£©µÈÁìÓòµÄÖÖÖ־ٴ룬¶ÔÈ«Çò8,300¶à¼Ò¹«Ë¾µÄ¿ÉÁ¬ÐøÐÔÉú³¤ÄÜÁ¦½øÐÐÆÀ¹À¡£È«Çò100Ç¿»ùÓÚ¶à´ï25ÏîÉæ¼°ESG²½·¥µÄÒªº¦¼¨Ð§Ö¸±ê£¬»ùÓÚ¹«Ë¾²ÆÎñÎļþ¡¢×ۺϱ¨¸æ»òÆäËû¹ûÕæÅû¶µÄÊý¾Ý½øÐÐÆÀ¹À¡£ng28ÄϹ¬Ôڸ߹Üн³êÖÐÌåÏÖ¿ÉÁ¬ÐøÉú³¤Ä¿±ê¡¢Ôöǿά»¤Ô±¹¤½¡¿µµÄ²½·¥¡¢Ô±¹¤±£´æÂʺÍÇé¿ö±£»¤²½·¥µÈÖ¸±ê·½ÃæÈÙ»ñ¸ß¶ÈºÃÆÀ¡£

 

ng28ÄϹ¬µÄÆóÒµÀíÄîÊǽ«»¼ÕßÀûÒæºÍÃñÖÚ½¡¿µ·ÅÔÚÊ×룬Âú×ãÆä¶àÑù»¯ÐèÇó£¬ÎªÌáÉýÆä¸£ìí×ö³öТ¾´¡£»ùÓÚÕâÖÖÌåÌùÈËÀཡ¿µ£¨hhc£¬human health care£©µÄÆóÒµÀíÄng28ÄϹ¬ÕýÔÚŬÁ¦Í¨¹ýÔöÇ¿ESG¼Æ»®ÓëÔö¼Ó·Ç²ÆÎñ¼ÛÖµÀ´¿ÉÁ¬ÐøµØÌáÉýÆóÒµ¼ÛÖµ¡£

 

 

ýÌåÁªÂç

Public Relations Department,

Eisai Co., Ltd.

+81-(0)3-3817-5120

 

±àºÅ£ºECN-2025-0008

ÃÀ¹úFDAÊÜÀíÓÃÓÚÖÎÁÆÔçÆÚ°¢¶û´Äº£Ä¬²¡µÄÂØ¿¨Ä¹Æ¤ÏÂ×Ô¶¯×¢Éäά³Ö¼ÁÁ¿µÄÉúÎïÖÆ¼ÁÉêÇë

ng28ÄϹ¬ºÍ²³½¡Ðû²¼£¬ÃÀ¹úʳƷҩƷ¼à¶½ÖÎÀí¾Ö£¨FDA£©ÒÑÊÜÀíÂØ¿¨Ä¹£¨lecanemab-irmb£©£¨ÃÀ¹úÉÌÆ·Ãû£ºLEQEMBI?£¬ÖйúÉÌÆ·Ãû£ºÀÖÒâ±£?£©Æ¤ÏÂ×Ô¶¯×¢É䣨SC-AI£©ÖÜά³Ö¼ÁÁ¿µÄÉúÎïÖÆÆ·Ðí¿ÉÉêÇ루BLA£©¡£ÂØ¿¨Ä¹ÓÃÓÚÖÎÁư¢¶û´Äº£Ä¬²¡£¨AD£©ÒýÆðµÄÇá¶ÈÈÏÖªÕϰ­ºÍÇá¶È°¢¶û´Äº£Ä¬²¡£¨Í³³ÆÎªÔçÆÚAD£©¡£PDUFA£¨´¦·½Ò©Óû§ÊÕ·Ñ·¨°¸£©µÄÉóÆÀÈÕÆÚÉ趨ÔÚ 2025Äê8ÔÂ31ÈÕ¡£

 

¸ÃÉúÎïÖÆÆ·Ðí¿ÉÉêÇ루BLA£©ÊÇ»ùÓÚClarity AD£¨Ñо¿301£©¿ª·Å±êÇ©À©Õ¹£¨OLE£©µÄÊý¾ÝÒÔ¼°ÊÓ²ìÊý¾ÝµÄ½¨Ä£¡£Èô»ñµÃÃÀ¹úʳƷҩƷ¼à¶½ÖÎÀí¾Ö£¨FDA£©µÄÅú×¼£¬ÂØ¿¨Ä¹½«³ÉΪһÖÖ¿ÉÔÚ¼ÒÖÐʹÓÃ×Ô¶¯×¢ÉäÆ÷ (AI) ¸øÒ©µÄ¿¹µí·ÛÑùÂѰ×ÁÆ·¨£¬ÇÒ×¢ÉäÀú³ÌÔ¤¼ÆÆ½¾ùºÄʱ15Ãë¡£×÷ΪÕýÔÚÉó²éµÄÿÖÜ360ºÁ¿Ëά³Ö¼ÁÁ¿ÖÎÁƼƻ®µÄÒ»²¿·Ö£¬ÒÑÍê³ÉÿÁ½Öܾ²Âö×¢É䣨IV£©Æðʼ½×¶ÎµÄ»¼Õß½«½ÓÊÜÿÖܼÁÁ¿¸øÒ©£¬¸Ã¼ÁÁ¿ÓÐÍûά³ÖÁÙ´²ºÍÉúÎï±ê¼ÇÎïÁÆÐ§¡£

 

°¢¶û´Äº£Ä¬²¡£¨AD£©ÊÇÒ»¸öÁ¬Ðø½øÐеÄÉñ¾­¶¾ÐÔÀú³Ì£¬Ê¼ÓÚ°ß¿é³Á»ý֮ǰ£¬²¢ÔÚÆäºó¼ÌÐøÉú³¤1,2,3¡£ÂØ¿¨Ä¹Í¨¹ýÁ¬ÐøÇå³ýÔ­ÏËάºÍ¿ìËÙÇå³ý°ß¿é¶Ô¿¹AD¡£Í¨¹ýÁ¬Ðø¸øÒ©£¬ÂØ¿¨Ä¹¿ÉÇå³ý¸ß¶¾ÐÔÔ­ÏËά£¬×ÝÈ»A¦Â°ß¿éÒÑ´Ó´óÄÔÖÐÇå³ý£¬Ô­ÏËάÈÔ»á¼ÌÐø¶ÔÉñ¾­ÔªÔì³ÉËðÉË¡£ÔÚ°¢¶û´Äº£Ä¬²¡Ð­»á¹ú¼Ê¼¯»á£¨AAIC2024£©ÉÏÐû²¼µÄÈýÄêºã¾ÃÓÃÒ©Êý¾Ý4±êÃ÷£¬ÔçÆÚ²¢Á¬ÐøµÄÖÎÁÆ×ÝÈ»ÔÚÄÔÄڰ߿鱻Çå³ýºó£¬Òà¿ÉÄÜÑÓ³¤ÖÎÁƵÄÒæ´¦¡£

 

SC-AI Ô¤¼Æ½«¼òµ¥Ò×Ó㬱ãÓÚ»¼Õß¼°Æä»¤Àíͬ°éʹÓ㬲¢¿É¼õÉÙ»¼Õßµ½Ò½Ôº»òÊäÒº³¡ºÏ¾ÍÕïµÄ´ÎÊýÒÔ¼°¾²Âö×¢ÉäµÄ»¤ÀíÐèÇó£¬Õ⽫ʹ»¼Õ߸üÈÝÒ×¼ÌÐøÎ¬³ÖÓÃÒ©£¬²¢ÓÐÖúÓÚ½øÒ»²½¼ò»¯ AD µÄÖÎÁÆÂ·¾¶¡£

 

ÂØ¿¨Ä¹ÒÑÔÚÃÀ¹ú¡¢ÈÕ±¾¡¢Öйú¡¢º«¹ú¡¢ÖйúÏã¸Û¡¢ÒÔÉ«ÁС¢°¢ÁªÇõ¡¢Ó¢¹ú£¨±±°®¶ûÀ¼³ýÍ⣩¡¢Ä«Î÷¸ç¡¢ºÍÖйú°ÄÃÅ»ñµÃÅú×¼£¬²¢ÒÑÏò°üÀ¨Å·ÃË£¨EU£©ÔÚÄÚµÄ17¸ö¹ú¼ÒºÍµØÇøÌá½»ÉÏÊÐÉêÇ룬²¢ÓÚ2024Äê11ÔÂÊÕµ½ÁËÅ·ÖÞÒ©Æ·ÖÎÀí¾ÖµÄÅú×¼½¨Òé¡£2024Äê6Ô£¬ÃÀ¹úʳƷҩƷ¼à¶½ÖÎÀí¾Ö£¨FDA£©ÊÜÀíÁ˾²Âöά³Ö¼ÁÁ¿£¨IV£©µÄÔö²¹ÉúÎïÖÆ¼ÁÐí¿ÉÉêÇ루sBLA£©£¬PDUFA£¨´¦·½Ò©Óû§ÊÕ·Ñ·¨°¸£©µÄÉóÆÀÈÕÆÚÉ趨ÔÚ2025Äê1ÔÂ25ÈÕ¡£

 

ÂØ¿¨Ä¹µÄÈ«Çò¿ª·¢ºÍ×¢²áÉêÇëÓÉng28ÄϹ¬Ö÷µ¼£¬¶ø²úÆ·ÔòÓÉng28ÄϹ¬ºÍ²³½¡ÅäºÏÉÌÒµ»¯ºÍÍÆ¹ã¡£ÆäÖУ¬ng28ÄϹ¬ÓµÓÐ×îÖÕ¾ö²ßȨ¡£

 

ýÌåÁªÏµ

ng28ÄϹ¬Öêʽ»áÉ繫¹Ø²¿ µç»°£º03-3817-5120

²³½¡¹«Ë¾¹«¹²ÊÂÎñ²¿ ÓÊÏä:public.affairs@biogen.com

 

 

²Î¿¼ÎÄÏ×

  1. LEQEMBI (lecanemab-irmb) injection, for intravenous use [package insert]. Nutley, NJ: Eisai Inc.
  2. Iwatsubo T, Irizarry M, van Dyck C, Sabbagh M, Bateman RJ, Cohen S. Clarity AD: a phase 3 placebo-controlled, double-blind, parallel-group, 18-month study evaluating lecanemab in early Alzheimer¡¯s disease. Presented at: CTAD Conference; November 29-December 2, 2022; San Francisco, CA.
  3. Hampel H, Hardy J, Blennow K, et al. The amyloid-¦Â pathway in Alzheimer¡¯s disease. Mol Psychiatry. 2021;26(10):5481-5503.
  4. Eisai presents long-term administration data of lecanemab at the Alzheimer’s Association International Conference (AAIC) 2024. Available at:https://www.eisai.co.jp/ir/library/presentations/pdf/4523_240731_1.pdf

 

ECN-2025-0007

ÒÔÈËΪ±¾´òÔì׿Խְ³¡Çé¿ö ng28ÄϹ¬ÖйúÁ¬ÐøÁùÄêÈÙ»ñ¡°Öйú½Ü³ö¹ÍÖ÷¡±ÈÏÖ¤

2025Äê1ÔÂ16ÈÕ£¬È«Çò½Ü³ö¹ÍÖ÷µ÷Ñлú¹¹£¨Top Employers Institute£©½ÒÏþÁË¡°2025Äê¶ÈÖйú½Ü³ö¹ÍÖ÷¡±Ãûµ¥£¬Æ¾½èÆäÒÔÆóÒµ×ÚÖ¼ºÍÒµÎñÇý¶¯µÄÈ˲ÅÕ½ÂÔ¡¢¶àÑùÐÔ¡¢¹«ÕýÐÔÓëÈÝÄÉÐÔ£¨DE&I£©µÄÆóÒµÎÄ»¯ÒÔ¼°Æä¿ÉÁ¬ÐøÉú³¤µÈÁìÓò½Ü³ö³É¼¨£¬ng28ÄϹ¬ÖйúÁ¬ÐøµÚÁùÄêÈÙ»ñ´ËÊâÈÙ¡£

ÄϹ¬NG28(Öйú)¹Ù·½ÍøÕ¾-µÇ¼Èë¿Ú

ng28ÄϹ¬È«Çò¸ß¼¶¸±×ܲá¢ng28ÄϹ¬Öйú×ܲ÷ëÑÞ»ÔŮʿÌåÏÖ£¬Õâ·ÝÈÙÓþ²»¿ÉÊǶÔng28ÄϹ¬Öйúºã¾Ã¼á³ÖÒÔÈËΪ±¾¡¢ÍÆ·¢¶¯¹¤È«ÃæÉú³¤µÄÆóÒÃ÷ÈÕ½ÂԵĿ϶¨£¬¸üÊǶÔng28ÄϹ¬Öйú½ñÄêÔÚDE&I·½ÃæÈ¡µÃÏÔÖø½øÕ¹µÄÈϿɡ£¶Ông28ÄϹ¬Öйú¶øÑÔ£¬»ý¼«ÍƹãDE&I£¬²»¿ÉÊÇng28ÄϹ¬ÖйúÆóÒµÎÄ»¯µÄÖØÒª×é³É²¿·Ö£¬¸üÊÇng28ÄϹ¬Öйú¼ùÐÐÆóÒµÀíÄîºÍʵÏÖÉç»á¼ÛÖµµÄÌåÏÖ¡£

×Ô½øÈëÖйúÊг¡30ÓàÄêÀ´£¬ng28ÄϹ¬ÖйúʼÖÕ½«Ô±¹¤ÊÓΪ×îÃû¹óµÄ×ʲú¡£ng28ÄϹ¬ÖйúÒÔÁ¢Òì¡¢×·Çó׿Խ¡¢Ö÷ÈËÎ̾«Éñ¡¢ÍŶÓÏàÖú¡¢ÕýÖ±³ÏÐÅΪ½¹µã¼ÛÖµ¹Û£¬»ý¼«¹¹½¨Ô½·¢¿ª·ÅÈÝÄɵÄHHC£¨Happy Healthy Company£©ÊÂÇéÇé¿ö£¬Í¨¹ý²»¾øÓÅ»¯ºÍÍØÕ¹È˲ÅÅàÑøÂ·¾¶£¬ÎªÔ±¹¤ÌṩÁÉÀ«¡¢¶àÔªµÄÉú³¤¿Õ¼äºÍ¹«ÕýµÄÉú³¤Ê±»ú¡£

ÉDE&I£¬ÒýÁìÖ°³¡ÐÂÃñË×

ÔÚÒÑÍùµÄÒ»ÄêÀng28ÄϹ¬ÖйúÒѽ«¡°¶àÑùÐÔ¡¢¹«ÕýÐÔÓëÈÝÄÉÐÔ¡±£¨DE&I£©ÌáÉýΪÆóÒµ½ø²½µÄ½¹µãÒýÇæÖ®Ò»¡£¹«Ë¾»ý¼«ÍÆÐÐDE&IÕ½ÂÔ£¬ÕâÒ»Õ½ÂԹᴮÕÐÆ¸Ñ¡°Î¡¢Ö°ÒµÅàѵÖÁְλ½úÉýµÄÿһ¸ö»·½Ú£¬Ö¼ÔÚÓªÔìÒ»¸ö¹«ÕýÎÞÆ«¡¢¹ã·ºÈÝÄɵÄÖ°ÒµÉú³¤¿Õ¼ä£¬ÈÃÿλԱ¹¤¶¼ÄÜÔÚ´Ë×Â׳Éú³¤²¢ÊµÏÖ¸öÈËDZÄÜ¡£

Ϊ¼¤Àø¸ü¶àÅ®ÐÔÁìµ¼ÕßÓÂÅÊá¯Áë¡¢¿ªÍØÐ¾³£¬ng28ÄϹ¬Öйú¾«ÐIJ߻®ÁË¡°Áìµ¼Á¦Ö®ËýÁ¦Á¿¡±¶Ô»°·Ã̸ÏîÄ¿£¬Ö¼ÔÚÕ¹ÏÖÅ®ÐÔÁìµ¼µÄ·ç·¶ÓëÁ¦Á¿¡£Í¬Ê±£¬¹«Ë¾»¹¾Ù°ìÁËÁìµ¼Á¦ÂÛ̳£¬Éî¶ÈÍÚ¾ò²¢·Å´ó¶àÔªÓëÈÝÄÉÐÔÁìµ¼×÷·çËù´øÀ´µÄÁ¢ÒìDZÄÜÓë¼ÛÖµ¡£

±ðµÄ£¬ng28ÄϹ¬Öйúͨ¹ý½¨Á¢¿ç²¿·ÖµÄHR×ÊÔ´¹²ÏíС×é¼°ÍÆ³ö¶¨ÖÆ»¯µÄÈ˲ÅÅàÑø¼Æ»®£¬²»µ«ÏÔÖøÔöÇ¿ÁËÔ±¹¤µÄ¹éÊô¸ÐÓëÍŶÓÈÏͬ¸Ð£¬¸üÀÖ³ÉÒý·¢ÁËÍŶӵĴ´Á¢Á¦ÓëÄý¾ÛÁ¦£¬ÎªÆóÒµÉú³¤×¢ÈëÁËÔ´Ô´²»¾øµÄ»îÁ¦Ó붯Á¦¡£

Á¬ÐøÍ¶È룬´òÔìѧϰÐÍ×éÖ¯

Ãæ¶Ô˲ϢÍò±äµÄÊг¡Çé¿ö£¬ng28ÄϹ¬ÖйúÉî¿ÌÈÏʶµ½£¬ÔÚ³äÂú²»È·¶¨ÐÔµÄʱ´ú£¬¶ÔÈ˲ŵÄÁ¬ÐøÍ¶×ÊÊÇ×î¾ß¼ÛÖµÇҼᶨ²»ÒƵÄÕ½ÂÔÑ¡Ôñ¡£

Ϊ¾«×¼ÏìÓ¦ÒµÎñÉú³¤µÄ¶àÔª»¯ÐèÇó£¬ng28ÄϹ¬Öйú¾«ÐÄÉè¼ÆÁË·ÖÌõÀí¡¢¿çÁìÓòµÄÈ˲ÅÅàÓýÌåϵ¡£ÔÚÊÂÒµ±¾²¿²ã¼¶£¬ÉèÁ¢ÁËÖ¼ÔÚÍÆ¶¯Á¬Ðø¸ß¼¨Ð§µÄרÏÄܼƻ®£¬ÒÔ¼°Ö¼ÔÚ¹¹½¨Ç¿½¡ÖÎÀíÕßÌݶӵĸßDZÁ¦È˲ÅÉú³¤ÏîÄ¿£¬È·±£Áìµ¼Á¦ÓëÒµÎñ¼¨Ð§µÄË«ÖØÌáÉý¡£ÔÚ¹«Ë¾ÕûÌå²ãÃæ£¬ng28ÄϹ¬ÖйúÓµÓÐÀúÊ·ÓÆ¾ÃµÄ¡°Æôº½¡±ÏîÄ¿£¬¸ÃÏîÄ¿Àú¾­Ê®Ä꣬Á¬ÐøÎªÏ²ãÖÎÀíÕ߸³ÄÜ£¬ÖúÁ¦ÆäÖ°ÒµÉú³¤ÓëÉú³¤¡£Í¬Ê±£¬2024Äêng28ÄϹ¬ÖйúÈ«ÐÂÍÆ³öÁË¡°Á캽Ա¼Æ»®¡±£¬Ö¼ÔÚÅàÑø²¢´¢±¸Î´À´µÄÖÐϲãÁìµ¼Á¦Á¿£¬Îª¹«Ë¾µÄ¾ÃÔ¶Éú³¤µÓÚ¨¼áʵµÄÈ˲Żù´¡¡£

ÕâЩ¼ÈÓеÄÈ˲ÅÉú³¤ÏîÄ¿ÒѾ­Îª¹«Ë¾ÊäËÍÁË´ó×ڲŻªºáÒçµÄ¾«Ó¢£¬ng28ÄϹ¬Öйú¼áÐÅ£¬Ëæ×ÅÐÂÏîÄ¿µÄ²»¾øÍƽø£¬½«Îª¹«Ë¾ÒµÎñµÄ¿ÉÁ¬Ðø²ýÊ¢ÓëÉú³¤Ð¢¾´¸ü¶àÁ¦Á¿£¬²»¾ø¼Ó¹Ìng28ÄϹ¬ÖйúÔÚÐÐÒµÖеÄÁìÏÈְλ¡£

×·Çó׿Խ£¬ÓªÔ콡¿µ¿ÉÁ¬ÐøµÄÖ°³¡Éú̬

ÔÚÇé¿öÓ뽡¿µ·½Ã棬ng28ÄϹ¬Öйú¼ÌÐø×ßÔÚÐÐҵǰÁС£ng28ÄϹ¬ÖйúÒ»Ö±ÖÂÁ¦ÓÚÍÆ¹ã½ÚÄÜ»·±£ÓëÂÌÉ«°ìÕýÒåÄ»ñµÃÁ˹ú¼Ò¼¶µÄÂÌÉ«°ì¹«ÈÏÖ¤¡£ng28ÄϹ¬ÖйúËÕÖݹ¤³§²»µ«ÈÙ»ñ½­ËÕÊ¡ÂÌÉ«µÍ̼Éú³¤ÈýʮǿÓëÖÇÄÜÖÆÔì³µ¼ä³Æºô£¬»¹Í¨¹ýÁËGB/T 23331-2020/ISO 50001:2018ÄÜÔ´ÖÎÀíÌåϵÈÏÖ¤£¬Á¬ÐøÒýÁìÖ°³¡Ïò½¡¿µ¡¢¿ÉÁ¬ÐøÆ«ÏòÂõ½ø¡£

ͬʱ£¬ng28ÄϹ¬ÖйúÉîÖªÔ±¹¤µÄÉíÐĽ¡¿µÊÇÆóÒµÉú³¤µÄ»ùʯ£¬ÍƳöÁ˰üÀ¨Áé»îÊÂÇéÖÆ¶È¡¢È«Ã潡¿µ¼ì²é¡¢¼ÒÍ¥ÓѺÃÕþ²ß¡¢ÒÔ¼°¸»ºñµÄÔ±¹¤ÉçÍÅÔ˶¯ÔÚÄÚµÄÈ«·½Î»¸£ÀûÌåϵ¡£ÕâЩ¾Ù´ë²»µ«ÌáÉýÁËÔ±¹¤µÄÐÒ¸£¸ÐºÍÂúÒâ¶È£¬Ò²½øÒ»²½ÀιÌÁËng28ÄϹ¬ÖйúHHC£¨Happy Healthy Company£©¹ÍÖ÷Æ·ÅÆ¡£

Ç¿»¯hhcÀíÄ¹²´´ÓÐÒâÒåµÄÊÂÇéÌåÑé

ng28ÄϹ¬ÖйúÉîÐÅ£¬ÊÂÇéµÄÒâÒåÔ¶²»Ö¹ÓÚıÉú£¬¸üÔÚÓÚ¶ÔÈËÀཡ¿µµÄТ¾´¡£2024Ä꣬ng28ÄϹ¬Öйú½øÒ»²½ÉÁËhhc£¨human health care£¬¡°ÌåÌùÈËÀཡ¿µ¡±£©ÀíÄ½«ÆäÈÚÈëµ½ÈÕ³£ÊÂÇéµÄÿһ¸ö»·½Ú¡£Í¨¹ý¾Ù°ìµÚÁù½ìhhc·å»á£¬ng28ÄϹ¬ÖйúÓë¸ü¶àÏàÖúͬ°éÅäºÏ̽ÌÖÈçºÎ½«hhcÀíÄîÀ©Õ¹µ½¸ü¹ã·ºµÄÁìÓò£¬´ÓÒ½Áƽ¡¿µµ½ÈÕ³£Éú»î£¬Îª¸ü¶àÈË´øÀ´¸£ìí¡£Í¬Ê±£¬ng28ÄϹ¬ÖйúÃãÀøÔ±¹¤»ý¼«¼ÓÈëhhcÏîÄ¿£¬Í¨¹ýʵ¼ù·¢Ã÷ÐèÇó¡¢Á¢Òì½â¾ö¼Æ»®£¬ÅäºÏ´´Á¢Ò»¸öÔ½·¢½¡¿µ¡¢ºÍгµÄÉç»á¡£

Õ¹ÍûδÀ´£¬ng28ÄϹ¬Öйú½«¼ÌÐø¼áÊØhhcÆóÒµÀíÄÖÂÁ¦ÓÚ´òÔìÒ»¸ö¿ìÀÖ¡¢½¡¿µ¡¢³äÂúÒâÒåµÄÊÂÇéÇé¿ö¡£ng28ÄϹ¬ÖйúÆÚ´ýÓëËùÓÐÔ±¹¤Ð¯ÊÖ¹²½ø£¬ÅäºÏÊéдng28ÄϹ¬ÖйúÔ½·¢»Ô»ÍµÄÃ÷Ìì¡£

±àºÅ£ºECN-2025-0006

Èð®ºÍÓ°Ïó²»ÔÙÃÔ·£¬ÓùâÓ°¼Í¼°¢¶û´Äº£Ä¬»¼Õß¼ÒÍ¥ÓÀºãµÄÃÀºÃ

¡°Èç¹û×îºóµÄ×îºó£¬ËüÕվɻá͵×ß°Ö°ÖÂèÂèµÄÓ°Ïó£¬ÎÒÏ룬ÎÒ¿ÉÒÔÓùâÓ°ÁôסÄÇЩÕä¹óµÄÈÕ×Ó¡£¡±°¢¶û´Äº£Ä¬²¡£¬ÏñÊÇÒ»¿ÅÄÔº£Öеġ°ÏðÆ¤²Á¡±£¬ÇÖÊ´×Å»¼ÕßµÄÓ°Ïó£¬Ö±ÖÁËûÃÇÍü¼Ç×Ô¼ºµÄÁµÈË¡¢×ÓÅ®ÒÔÖÁËùÓÐÉî°®¹ýµÄÈË¡£

µ«ÈËÀàÖ®ËùÒÔ¼áÇ¿£¬ÊÇËûÃÇÃ÷°×ÔÚ¶ÌÔݵÄÉúÃüÂóÌÖУ¬»ý¼«¶Ô¿¹Î´ÖªµÄ²¡Ä§£¬Õäϧÿ¸öµ±Ï£¬Áô´æÄÇЩÐÒ¸£µÄ˲¼ä¡£

2025ÄêÐÂÄêÒÁʼ£¬¡°ÐÒ¸£È«¼Ò¸£¡ª¡ªÈð®ºÍÓ°Ïó²»ÔÙÃÔ·¡±°¢¶û´Äº£Ä¬²¡£¨AD£©¹Ø°®¹«ÒæÐж¯ÔÚÉϺ£ÕýʽÆô¶¯¡£¶àλAD»¼Õß¼ÒÍ¥¼ÓÈëÁËÕâÒ»ÏîÄ¿£¬×ÓÅ®ÃÇÅã°éâïÊÑÀ´µ½º£ÂíÌåÕÕÏà¹Ý£¬Ñ¡ÔñÓùâÓ°¼Í¼ÏÂÐÒ¸£µÄ¼ÒÍ¥»ØÒä¡£

ÔÚÇ×ÊÖΪÄãÉè¼ÆµÄ¡°¼Ò¡±ÖÐÁôÏÂÎÒÃǵÄÈ«¼Ò¸£

À´×ÔÉϺ£µÄÑîÊåÊå¡°¸ÕÖªµÀËý»¼²¡µÄʱºò£¬ÎÒÃÇÒ²ºÜÊÇÍ´¿àºÍÕÛÄ¥£¬µ«ÐÒ¿÷ÎÒÃǼá³ÖÁËÏÂÀ´£¬ÐÄ̬ҲԽ·¢Æ½ºÍ£¬Èç¹ûÆäËûµÄ»¼Õß¼ÒÍ¥ÄÜ´ÓÎÒÃǵľ­ÀúÖлñµÃһЩ¾«ÉñÖ§³Ö£¬ÎÒÃÇÒ²ºÜÊÇÀÖÒâ¡£¡±ÑîÊåÊåÌåÏÖ£¬ÎÒÃÇҲϣÍû¸ü¶àµÄ°¢¶û´Äº£Ä¬²¡»¼ÕßÄܹ»ÖØÊÓÔçÆÚµÄÔ¤·ÀºÍÖÎÁÆ£¬ÔÚ¼²²¡³õÆÚÈ¥¸ÉÔ¤ºÍÖØÊÓ£¬ÊÇÓÐÏ£ÍûÑÓ»º¡£

ÑîÊåÊåºÍκÒÌÂ裬ÔÚ×Ô¼ºÃλðãµÄ¼ÒÖУ¬ºÍ¶ù×Ó¡¢¶ùϱÁôÏÂÁË2025ÄêµÄµÚÒ»ÕÅÈ«¼Ò¸££¬ÎºÒÌÂè½¾°ÁµØ¸æËßÅÄÉãÍŶÓ£¬¡°ÏÈÉúÔÚÉè¼Æ×Ô¼ºµÄ¼ÒÖÐÇã×¢Á˲»ÉÙÐÄѪ£¬ÎÒÃÇÒѾ­×¡Á˰뱲×ÓÁË¡£¡±

ÄϹ¬NG28(Öйú)¹Ù·½ÍøÕ¾-µÇ¼Èë¿ÚÑîÊåÊ廹¼ÇµÃÄÇÊÇ2023Ä꣬һÏòÈȰ®ÌøÎ裬¶ÔÉú»î³äÂúÈÈÇéµÄÀϰ飬ͻȻ¿ªÊ¼½¡Íü£¬ÔçÉϳÔʲôÂíÉϾͼDz»×¡ÁË£¬ÓÀÔ¶²»¼ÇµÃ¹ØµÆ£¬¡°ÄÇʱºòÎҾ;õµÃËýËÆºõ²î³Ø¾¢ÁË¡£¡±ËæºóËûÃǼ¸¾­²¨ÕÛ£¬¸Ïµ½ÉϺ£Èð½ðÒ½ÔºÉñ¾­ÄÚ¿ÆÌÀÜö¶¬Ö÷Èδ¦ÎÊÕ×îÖÕÈ·ÕïΪ°¢¶û´Äº£Ä¬²¡¡£

Ô­±¾ÐÒ¸£µÄ¼ÒͥͻÔâ±ä¹Ê£¬ÎÂÈáµÄÀϰéÒ²±äµÃ¼±Ôê¡£ÐÒ¿÷κÒÌÂèÊÇÇá¶È°¢¶û´Äº£Ä¬²¡£¬ÁíÓÐÓÐЧµÄÒ©Îï¿ÉÒÔ¿ØÖÆ¡£ÑîÊåÊ廹¼ÇµÃÄÇЩ±¼¸°º£Äϲ©÷¡µÄÈÕ×Ó¡£¡°ÄÇʱºòҪÿÁ½ÖÜÈ¥Ò½Ôº´òÒ»´ÎÂØ¿¨Ä¹£¬ÐÒ¿÷Ч¹û»¹²»´í¡£Ä¸Ç×ÓÃÒ©ºó×î´óµÄ±ä¸ïÊÇÐÔ¸ñ±äµÃ¸üÈáºÍÁË£¬¸úËýÁÄÌ죬ËýÒ²²»»áÔÙһֱ˵ÒÔǰµÄÊÂÇ飬¶øÊÇÄܹ»¼ÇµÃ×òÌì×öÁËʲô¡£¡±ÑîÊåÊåµÄ¶ùϱ»ØÒä¡£

ÄϹ¬NG28(Öйú)¹Ù·½ÍøÕ¾-µÇ¼Èë¿Ú

¡°¸ÕÖªµÀËý»¼²¡µÄʱºò£¬ÎÒÃÇÒ²¸ÐÓ¦ºÜÊÇÍ´¿àºÍÊÜÕÛÄ¥£¬µ«ÐÒ¿÷ÎÒÃǼá³ÖÁËÏÂÀ´£¬ÐÄ̬ҲԽ·¢Æ½ºÍ£¬Èç¹ûÆäËûµÄ»¼Õß¼ÒÍ¥ÄÜ´ÓÎÒÃǵľ­ÀúÖлñµÃһЩ¾«ÉñÖ§³Ö£¬ÎÒÃÇÒ²ºÜÊÇÀÖÒâ¡£¡±ÑîÊåÊåÌåÏÖ£¬ÎÒÃÇҲϣÍû¸ü¶àµÄ°¢¶û´Äº£Ä¬²¡»¼ÕßÄܹ»ÖØÊÓÔçÆÚµÄÔ¤·ÀºÍÖÎÁÆ£¬ÔÚ¼²²¡³õÆÚÈ¥¸ÉÔ¤ºÍÖØÊÓ£¬ÊÇÓÐÏ£ÍûÑÓ»º£¬ÉõÖÁÄæ×ªµÄ¡£¡±

¼²²¡µÄÕÛĥûÓÐÈ¡ÏûÀÏÁ½¿ÚÈȰ®Éú»îµÄÐÄ£¬2010Ä꣬ҲÊÇÕâ¶ÔØøÙ³µÄÕäÖé»é£¬Ð¯ÊÖÏà°é30Ä꣬ΪÁ˼ÍÄîÕâ¸öÌØ±ðµÄÈÕ×Ó£¬ÑîÊåÊåÇ×ÊÖ×öÁËÒ»Ì׼Ҿߣ¬ÎªÕâ¸öÔ­À´¾ÍÎÂůµÄ¼ÒÔö¼ÓÁ˸ü¶àµÄÎÂܰ¡£¶ø°®³ª¸èÌøÎèµÄκÒÌÂ裬ÔÚÅÄÉã¼ä϶³ªÆðÁ˸èÀ´£¬ÎÂůµÄ¸èÉù£¬Ñ¬È¾ÁËÏÖ³¡µÄÿһ¸öÈË¡£

Éú»î²¢²»¿ÉÄÜÒ»·«·ç˳£¬µ«¶ÔÑîÊåÊåºÍκÒÌÂèÀ´Ëµ£¬ÎÞÂÛºÎÖÖ¾³Óö£¬¶¼¿ÉÒÔÓùâÓ°¼Í¼ÏÂÕâÒ»¿ÌµÄÐÒ¸££¬¶¼¿ÉÒÔÓøèÉùÁôÏÂÐÒ¸£µÄÓàÔÏ¡­¡­

Äã´øÎÒ³¤´ó£¬ÎÒÅãÄã±äÀÏ

ÔÚÅ®¶ùÞ¥ÃÀÑÛÀÂèÂèÒ»Ö±ÊÇ×Ô¼ºµÄÄ£·¶¡£¡°ÎÒÃǼÒÊÇÎåºÃ¼ÒÍ¥£¬Ð¡Ê±ºòÎÒ¿´×ÅËýÎÞ΢²»ÖÁµÄÕÕ¹Ë×𳤣¬ÉíÌåÁ¦ÐеظæËßÎÒÃÇҪТ˳×𳤣¬ÏÖÔÚÂÖµ½ÎÒÀ´ÕÕ¹ËËýÁË¡£¡±

ÄϹ¬NG28(Öйú)¹Ù·½ÍøÕ¾-µÇ¼Èë¿Ú

Ò»Éú¶¼ÔÚΪ¼ÒÍ¥²ÙÀ͵ķëÒÌÂ裬ÊǹŰåµÄÂèÂ裬ҲÊǼÒÍ¥Öеĸ÷È˳¤¡£1988Äê7Ô£¬ÒòΪÕÕ¹ËÀÏÈË£¬Í¨¹ýÉçÇø¾Óί»áÍÆ¼ö£¬»ñµÃÁËÉϺ£Êо´ÀϺÃ×ÓÅ®½ð°ñ½±¡£¡°ÆäʱÁì½±µÄʱºòÉϺ£ÊÐÊг¤Ç××ÔΪËý°ä½±¡£¡±Þ¥ÃÀ»ØÒäµÀ¡£ÑÔ´«Éí½ÌÏ£¬Þ¥ÃÀÔÚÂèÂ軼²¡ºóÒ²½ÓÏÂÁËÕչ˷ëÒÌÂèµÄÖØÈΡ£¡°ÂèÂèÈ·ÕïÖ®ºó£¬·ÅÆúÁ˳ö¹úºÍÆäËûÊÂÇéµÄÉú³¤Ê±»ú£¬¾ö¶¨ÁôÏÂÀ´ÅãËýÒ»ÆðÃæ¶Ô¼²²¡¡±¡£°¢¶û´Äº£Ä¬²¡ÈËÐèÒª¼ÒÈ˵ÄÕÕ»¤£¬Þ¥ÃÀµ£¸ºÆðÁËÕâ¸öÔðÈΣ¬Ò»Åã¾ÍÊÇ12Äê¡£

½ñÄ꣬ޥÃÀºÍÂèÂè·ëÒÌÂèÀ´µ½º£ÂíÌåÅÄÉãÊôÓÚĸٶþÈ˵ÄÈ«¼Ò¸££¬Èç¹û²»ÊDZ»¼û¸æ£¬ÄãºÜÄÑ·¢Ã÷·ëÒÌÂè»áÊÇÒ»Ãû°¢¶û´Äº£Ä¬²¡»¼Õß¡£ÔÚÏÖ³¡£¬Ëý¸æËßÅÄÉãÍŶÓ£¬ÕâÊÇËýµÚÒ»´Î»¯×±£¬»¯×±ÆÚ¼ä¸üÊÇÈ̲»×¡¸ø¸÷È˳ªÆðÁËÓ¢Îĸè¡£

¡°ÂèÂèÊÇÎҵĽ¾°Á£¬µ±ÄêÈ«¹úÐû´«¾´Àϰ®Ó×ÐÂÃñË×£¬ÂèÂè»ñÊм¶½±ÏîµÄÇìÐÒʼ£±»¹ã·º±¨µÀ£¬¹«¹²¶¼±»Ëý¸Ð¶¯¡£ÏÖÔÚ»¼²¡ÁË£¬ËýÒ²ÊÇÒ½ÉúÑÛÖÐΪÊýδ¼¸µÄÄ£·¶»¼Õߣ¬×ñÒ½Öö£¬»ý¼«ÖÎÁÆ£¡¡±Ìá¼°¼ÓÈëÕâ´ÎÅÄÉãµÄ³õÖ¾£¬Þ¥ÃÀ˵£¬¡°ÎÒÃÇÏ£ÍûÄܸøÍ¬ÑùÉî´¦ÔÚ¼²²¡ÖеļÒÍ¥´øÀ´Ò»Ð©×ÆË¸£¬±ÈÆðÈÃÀÏÈË×ÔÉú×ÔÃ𣬻ý¼«µØÖÎÁÆ£¬ÎÂůµÄÊØ»¤£¬²ÅÊÇÎÒÃÇÖлªÃñ×åµÄ¹Å°å¡£¡±

ÄϹ¬NG28(Öйú)¹Ù·½ÍøÕ¾-µÇ¼Èë¿Ú

ÏëÈÃÄãÒ»Ö±Ò»Ö±¼ÇµÃÎÒÃÇ

ͬÑùÀ´×ÔÉϺ£µÄÁõÒ¯Ò¯Ò»¼ÒÒ²ÊÇÈç´Ë£¬½ñÄêËûÔÚ¶ù×ÓºÍÅ®¶ùµÄÁìµ¼ÏÂÅÄÉãÁË×îÌØ±ðµÄÈ«¼Ò¸£¡£¡°ÖªµÀ¸¸Ç×»¼²¡µÄʱºò£¬ÊÇÒòΪËûµÄÖÖÖÖÒì³££¬ºÃ±ÈÎç˯ºó·Ö²»ÇåÌìºÚÕÕ¾ÉÌìÁÁ£¬Ã÷Ã÷ÃÅÒѾ­ËøÁË£¬µ«ÕÕ¾ÉÖØ¸´¼ì²é£¬ÒÉÐIJ¡ºÜÊÇÖØ¡£¡±ÁõŮʿ»ØÒäµÀ£¬¡°ÎÒÄÌÄÌÒ²ÊÇÕâÖÖ¼²²¡£¡ÔÚÎÒµÄÓ¡ÏóÖУ¬ËýÀúÀ´Ã»ÓмǵùýÎÒ£¬Ò²²»¼ÇµÃËý¶ù×ÓÅ®¶ù¡£¡±

ÄϹ¬NG28(Öйú)¹Ù·½ÍøÕ¾-µÇ¼Èë¿Ú

ÁõÒ¯Ò¯×îÖÕÔÚÉϺ£Î÷ÔÀÒ½ÔºÉñ¾­ÄÚ¿ÆÈ·ÕïΪ°¢¶û´Äº£Ä¬²¡ÔçÆÚ£¬Õ·×ªºó½ÓÊÜÁËÂØ¿¨Ä¹µÄÖÎÁÆ¡£¡°±ÈÆðÒ©ÎעÉä¶ÔËûÀ´Ëµ£¬¿ÉÄÜÒÀ´ÓÐÔ¸ü¸ßһЩ£¬²¢ÇÒÓÃÍêÒ©ËûµÄ×´¿öÒ²»ñµÃÁË»º½â¡£¡±

Èç½ñÁ½¸ö×ÓÅ®»¹×ÜÊDz»¶¨ÐİѸ¸Ç×µ¥¶À·ÅÔÚ¼ÒÀһ¶¨ÒªÈ¥ÉϰàµÄʱºò£¬ÁõÏÈÉúºÍÁõŮʿҲ»á²»¾ø´òµç»°¸ø¸¸Ç×£¬ÎÊÒ»ÎÊËûµÄÇé¿ö¡£Äܹ»¸ú¸¸Ç×¶à˵˵»°£¬Óиü¶àÕ䲨µÄÓ°Ïó£¬ÊÇËûÃǵ±ÏÂ×îÖØÒªµÄʶù¡£

ÄϹ¬NG28(Öйú)¹Ù·½ÍøÕ¾-µÇ¼Èë¿Ú

Èçͬ×ß½øÕÕÏà¹ÝµÄǧǧÍòÍò¸ö°¢¶û´Äº£Ä¬¼ÒÍ¥Ò»Ñù£¬Ã¿Ò»¸ö¼ÒÍ¥Öж¼ÓÐÒ»¸ö¹ØÓÚ°®µÄ¹ÊÊ¡£

µ«Ãæ¶Ô¼²²¡£¬ÔçÕïÔçÖÎÈÔÈ»ÊÇÁôסӰÏóµÄÒªº¦£¬°¢¶û´Äº£Ä¬²¡½øÕ¹µ½ÖÐÍíÆÚ£¬»áÈû¼Õßʧȥ»ù±¾µÄÉú»î×ÔÀíÄÜÁ¦£¬¿´»¤ÕßÃǾ­³£ÐèÒª24Сʱ¿´»¤¶ø²»¿°Öظº¡£´ó¶¼×ÓŮֻÄÜÑÛÕöÕö¿´×ű»âïÊÑÒÅÍü¡£

¶øÓÉÇá¶ÈÈÏÖªÕϰ­ºÍÇá¶È³Õ´ôÔòÊǰ¢¶û´Äº£Ä¬²¡µÄ¡°ÖÎÁƻƽðÆÚ¡±£¬ÊÇĿǰAD»¼Õß½ÓÊܶÔÒò°ÐÏòÖÎÁƺóΨһ¿ÉÒÔÑÓ»º¼²²¡½øÕ¹µÄʱÆÚ¡£Ä¿Ç°¿ÉÒÔͨ¹ýÒ»¹ÜѪ½øÐа¢¶û´Äº£Ä¬²¡Î£º¦¿ìËÙÔçɸ£¬×¥×¡ÖÎÁÆ»Æ½ð´°¿ÚÆÚ, Ôç¸ÉÔ¤Ôç»ñÒæ£¡

ÒÅÍüÊǰ¢¶û´Äº£Ä¬²¡µÄ¿ªÊ¼£¬¾Ü¾ø±»ÒÅÍü£¬ÐèҪȫÉç»áÌá¸ßÈÏÖª¡£Óð®È¥´´Á¢¸ü¶àÃÀºÃµÄ˲¼ä£¬ÓÿÆÑ§µÄÕïÁÆÈ¥ÊØ»¤×îÕä¹óµÄÓ°Ïó£¬ÊÇËùÓа¢¶û´Äº£Ä¬²¡¼ÒÍ¥ÅäºÏµÄÌôÕ½¡£

¸ÃÔ˶¯Óɼô°®¹«ÒæÌᳫ£¬ng28ÄϹ¬ÖйúÓ뺣ÂíÌåÕÕÏà¹Ý¹«ÒæÖ§³Ö¡£

±àºÅ£ºECN2025-0004

Î÷°²½»Í¨´óѧҩѧԺ¡°ng28ÄϹ¬Öйú½±½Ìѧ½ð¡±°ä½±ÒÇʽԲÂú¾ÙÐÐ

2025Äê1ÔÂ11ÈÕ£¬Î÷°²½»Í¨´óѧҩѧԺÖ÷°ìµÄ¡°ng28ÄϹ¬Öйú½±½Ìѧ½ð¡±°ä½±ÒÇʽÔÚÎ÷°²½»´óÒ©Ñ§ÔºÂ¡ÖØ¾ÙÐС£´Ë´Î½±½Ìѧ½ðÓÉng28ÄϹ¬£¨ÒÔϼò³Æ¡°ng28ÄϹ¬Öйú¡±£©¾èÔù£¬Ö¼ÔÚÖ§³Öҩѧ½ÌÓýÊÂÒµµÄÉú³¤£¬¼¤ÀøÓÅÐãʦÉú»ý¼«½øÈ¡£¬ÎªÈËÀàµÄ½¡¿µÊÂҵТ¾´Á¦Á¿¡£ng28ÄϹ¬¸ß¼¶´óÇø¾­ÀíÀ×Ö¾Ó¡¢Î÷°²½»Í¨´óѧҩѧԺԺ³¤ÍõËÃÜË¡¢Êé¼ÇÕÅÑåÃñ¡¢¸±Ôº³¤·½ÓîÒÔ¼°»ñ½±½ÌʦºÍ»ñ½±Ñ§Éú´ú±í³öϯÁ˴˴ΰ佱ÒÇʽ¡£

ÄϹ¬NG28(Öйú)¹Ù·½ÍøÕ¾-µÇ¼Èë¿Ú

×Ô2023ÄêÆð£¬ng28ÄϹ¬Öйú½«Á¬Ðø5ÄêÔÚÎ÷°²½»Í¨´óѧҩѧԺÉèÁ¢¡°ng28ÄϹ¬Öйú½±½Ìѧ½ð¡±£¬Ã¿Äê¾èÔù5ÍòÔª£¬Î÷°²½»Í¨´óѧҩѧԺ¡°ng28ÄϹ¬Öйú½±½Ìѧ½ð¡±½«»Ý¼°65ÃûÓÅÐãµÄÎ÷°²½»´ó½ÌʦºÍѧÉú¡£

ÄϹ¬NG28(Öйú)¹Ù·½ÍøÕ¾-µÇ¼Èë¿Ú

°ä½±ÒÇʽÉÏ£¬À×Ö¾Ó¾­ÀíÏêϸ½éÉÜÁËng28ÄϹ¬ÖйúµÄhhc£¨human health care£©ÀíÄ¼´¡°ÌåÌùÈËÀཡ¿µ¡±¡£ËûÇ¿µ÷£¬ng28ÄϹ¬ÖйúÒ»Ö±½«ÌáÉýÈËÀཡ¿µË®Æ½×÷ΪÆóÒµµÄ×ÚÖ¼£¬Éî֪ҽѧ½ÌÓý¹ØÓÚÅàÑøÎ´À´Ò½Ñ§È˲ŵÄÖØÒªÐÔ¡£Òò´Ë£¬ng28ÄϹ¬ÖйúÖÂÁ¦ÓÚÓëÖйú¸÷´óҽѧԺУÏàÖú£¬Í¨¹ýÉèÁ¢½±½Ìѧ½ð¡¢¿ªÕ¹¿ÆÑÐÏîÄ¿µÈ·½·¨£¬Ö§³Öҽѧ½ÌÓýÊÂÒµµÄÉú³¤£¬ÎªÉç»áÅàÑø¸ü¶àÓÅÐãµÄҽҩѧרҵÈ˲Å¡£

ÍõËÃÜ˶Ông28ÄϹ¬ÖйúµÄ¿¶¿®¾èÔùÌåÏÖÖÔÐĵÄлл¡£ËýÃãÀøÑ§ÉúÃÇÒªÓÂÓÚ¼ÌÐø¡¢¸ÒÓÚÁ¢Ò죬½«Ëùѧ֪ʶӦÓÃÓÚʵ¼ùÖУ¬ÎªÈËÀàµÄ½¡¿µÊÂҵТ¾´×Ô¼ºµÄÁ¦Á¿¡£ËýÏ£ÍûѧÉúÃÇÄܹ»ÕäϧÓëng28ÄϹ¬ÖйúÕâÑùµÄÓÅÐãÆóÒµÏàÖúµÄʱ»ú£¬»ý¼«Í¶Éíҽѧ½ÌÓýÊÂÒµ£¬ÎªÖйúµÄÒ½Ò©ÊÂÒµ×ö³ö¸ü´óµÄТ¾´¡£

Ŀǰ£¬ng28ÄϹ¬ÖйúÔÚÖйú8ËùÒ½Ò©Àà¸ßµÈԺУÉèÁ¢ÁËng28ÄϹ¬Öйú½±Öúѧ½ð£¬ng28ÄϹ¬Öйú½«¼ÌÐø±ü³Ö¡°hhc¡±µÄÆóÒµÀíÄΪÖйúҽѧ½ÌÓýÊÂÒµµÄÉú³¤Ð¢¾´¸ü¶àµÄÁ¦Á¿¡£

±àºÅ£ºECN-2025-0005

¹ØÓÚÂØ¿¨Ä¹ÑÓ»º°¢¶û´Äº£Ä¬²¡½øÕ¹µÄ²¿·Ö»úÖÆµÄ˵Ã÷

ÓɽðÔó´óѧµÄҽѧ¡¢ÖÆÒ©ºÍ½¡¿µ¿ÆÑ§Ñо¿ËùKenjiro Ono£¨Ð¡Ò°ÏͶþÀÉ£©½ÌÊÚÁìµ¼µÄÑо¿Ð¡×éÓëng28ÄϹ¬Öêʽ»áÉçÏàÖú£¬ÀûÓÃпª·¢µÄÂØ¿¨Ä¹Ïà¹Øµí·ÛÑùÂѰ×-¦ÂÔ­ÏËά£¨Lec-PF£©ÕÉÁ¿ÏµÍ³Ö¤Ã÷£¬Óë·Ç°¢¶û´Äº£Ä¬²¡±ÈÕÕ×éÏà±È£¬°¢¶û´Äº£Ä¬²¡»¼Õß´ÓÇá¶ÈÈÏÖªÕϰ­µ½Çá¶ÈºÍÖØ¶È³Õ´ôµÄ¸÷¸ö½×¶ÎÄÔ¼¹ÒºÖеÄLec-PFŨ¶È¶¼ÓÐËùÉý¸ß¡£±ðµÄ£¬ÕâÏîÑо¿»¹·¢Ã÷£¬ÄÔ¼¹ÒºÖÐ Lec-PFµÄŨ¶ÈÓë·´Ó¦Éñ¾­±äÐÔµÄÉúÎï±ê¼ÇÎïÓÐÃ÷ÏÔµÄÏà¹ØÐÔ¡£

ÂØ¿¨Ä¹ÊÇÒ»ÖÖÆæÌصÄË«ÖØ×÷Óÿ¹Ì壬³ýÁËÇå³ý°ß¿éÍ⣬»¹Ñ¡ÔñÐÔ½áºÏµí·ÛÑùÂѰ×-¦ÂÔ­ÏËά£¨PF£©£¬ÊÇÖÎÁư¢¶û´Äº£Ä¬²¡£¨AD£©ÒýÆðµÄÇá¶ÈÈÏÖªÕϰ­ºÍÇá¶È°¢¶û´Äº£Ä¬²¡£¨Í³³ÆÎªÔçÆÚAD£©»¼ÕßµÄÒ»ÖÖÒ©Îï¡£ÕâÏîÑо¿µÄ½á¹û±êÃ÷£¬ÂØ¿¨Ä¹²¶»ñµÄPF£¨Lec-PF£©±£´æÓÚ°¢¶û´Äº£Ä¬²¡»¼ÕßµÄÄÔ¼¹ÒºÖУ¬Lec-PFÊÇÒ»Ö־綾µÄ²¡ÀíÂѰ×£¬»áµ¼ÖÂÉñ¾­ÍËÐÐÐԱ䡣ÕâÏîÑо¿½ÒʾÁËÂØ¿¨Ä¹¼õ»º°¢¶û´Äº£Ä¬²¡½øÕ¹µÄ²¿·Ö»úÖÆ¡£

»ùÓÚÕâЩ·¢Ã÷£¬Î´À´¿ÉÄÜÔÚÂØ¿¨Ä¹ÖÎÁÆÇ°ºóÕÉÁ¿ÄÔ¼¹ÒºÖÐLec PFµÄŨ¶È£¬ÒÔÆÀ¹ÀÖÎÁÆÐ§¹û¡£±ðµÄ£¬ÓÉÓÚÄÔ¼¹ÒºÖÐLec-PFµÄŨ¶ÈÓë×ÜtauºÍÉñ¾­¿ÅÁ£ÂѰ׵ÈÉñ¾­ÍËÐÐÐÔ±ê¼ÇÎïÃÜÇÐÏà¹Ø£¬Ô¤¼ÆÕâЩ·¢Ã÷Ò²¿ÉÓÃÓÚÔ¤²â°¢¶û´Äº£Ä¬²¡»¼ÕßµÄÔ¤ºó¡£

ÕâÏîÑо¿ÓÚ2025Äê1ÔÂ6ÈÕ18:30£¨ÃÀ¹ú¶«²¿±ê׼ʱ¼ä£©Ðû²¼ÔÚ¹ú¼ÊѧÊõÆÚ¿¯¡¶Annals of Neurology¡·µÄÍøÂç°æÉÏ¡£

Ñо¿Åä¾°ºÍÄ¿µÄ

µí·ÛÑùÂѰ׼¶Áª¼Ù˵ÊǹØÓÚAD²¡ÒòµÄÖ÷ÒªÀíÂÛ£¬¸Ã¼Ù˵ÈÏΪ¦Âµí·ÛÑùÂѰף¨A¦Â£©ÔÚÉñ¾­ÔªÍâÒì³£¾Û¼¯£¬ËæºóÐγÉtauÉñ¾­Ô­ÏËά²ø½á£¬¶ÔÉñ¾­ÔªÔì³ÉËðÉË£¬²¢µ¼Ö¼²²¡±¬·¢¡£Ô­ÏËάÐÎ̬µÄ¦Âµí·ÛÑùÂѰױÈÏËάºÍ°ß¿éÐÎ̬¸ü¾ßÉñ¾­¶¾ÐÔ£¬ºóÕßÊÇÒì³£¾Û¼¯A¦ÂµÄ×îºó½×¶Î£¬Òò´ËÈÏΪPF¿ÉÄܻᵼÖÂÉñ¾­ÍËÐÐÐԱ䣨²Î¿¼ÎÄÏ×£ºAmin LºÍHarris DA.2012£©¡£ÂØ¿¨Ä¹ÊÇÒ»ÖÖ¿¹µí·ÛÑùÂѰ×-¦ÂÔ­ÏËά¿¹Ì壬×Ô2023ÄêÒÔÀ´Ò»Ö±ÓÃÓÚÖÎÁÆÔçÆÚAD¡£È»¶ø£¬´ËǰûÓйØÓÚÕÉÁ¿ÈËÀàÉúÎïÑù±¾ÖÐPFŨ¶ÈµÄ±¨¸æ£¬²¢ÇÒ×÷ÎªÂØ¿¨Ä¹ÖÎÁưеãµÄPFÔÚÕû¸öADÁ¬ÐøÌåÖеÄÂþÑÜÇé¿öÉв»Çå³þ¡£

ÔÚÕâÏîÑо¿ÖУ¬Ñо¿Ð¡×éʹÓÃпª·¢µÄ¸ßÁéÃô¶ÈLec-PFÕÉÁ¿ÏµÍ³£¬ÕÉÁ¿ÁËÁÙ´²Ç°AD¡¢ADÒýÆðµÄÇá¶ÈÈÏÖªÕϰ­ºÍAD³Õ´ôÊÜÊÔÕßÒÔ¼°SNAP£¨ÒÉËÆ·ÇAD²¡ÀíÉúÀíѧ£©»¼ÕߺÍÈÏÖª¹¦Ð§Õý³£ÕßµÄÈËÄÔ¼¹Òº£¨CSF£©ÖÐLec-PFµÄŨ¶È£¬²¢ÆÊÎöÁËLec-PFÓëA¦Â40¡¢A¦Â42Á׵ĹØÏµ¡¢ ²¢ÆÊÎöÁËLec-PFÓëA¦Â40¡¢A¦Â42¡¢Á×Ëữtau£¨p-tau£©181£¨*9£©¡¢p-tau 217¡¢×ÜtauºÍÉñ¾­Á£ÂѰ×Ö®¼äµÄ¹ØÏµ¡£

Ñо¿½á¹û×ÛÊö

ADÒýÆðµÄÇá¶ÈÈÏÖªÕϰ­»ò³Õ´ô»¼Õߣ¨Í¼1ÖеÄMCI+¡¢AD+×飩µÄLec PF CSFŨ¶ÈÃ÷ÏÔ¸ßÓÚÈÏÖª¹¦Ð§Õý³£µÄ»¼Õߣ¨Í¼ÖеÄYNCºÍAMC×飩¡£

¶ÔÄÔ¼¹ÒºÖÐLec-PFµÄŨ¶ÈÓëÆäËûÄÔ¼¹Òº±ê¼ÇÎA¦Â42¡¢A¦Â42/40±ÈÖµ¡¢p-tau 181¡¢p-tau217¡¢×Ütau¡¢Éñ¾­¿ÅÁ£ÂѰף©Ö®¼ä½øÐÐÁËÏà¹ØÐÔÆÊÎö¡£Í¼2ÏÔʾÁËLec PFºÍÖÖÖÖCSF±ê¼ÇÎïÖ®¼äµÄSpearmanÏà¹ØÏµÊý£¨95%ÖÃÐÅÇø¼ä£©¡£ÔÚËùÓÐÊÜÊÔÕßÖУ¨Í¼2ÖеĺÚÏߣ©£¬ÄÔ¼¹ÒºÖÐLec PFŨ¶ÈÓëa¦Â42¡¢a¦Â42/40±ÈÖµ¡¢p-tau 181¡¢p-tau217¡¢×ÜtauºÍÉñ¾­¿ÅÁ£ÂѰ׳ÊÏà¹ØÐÔ£¬SpearmanϵÊýΪ0.2»ò¸ü¸ß¡£ÖµµÃ×¢ÒâµÄÊÇ£¬µ±½ö¹Ø×¢A¦ÂÑôÐÔ×éʱ£¨Í¼2ÖеĺìÏߣ©£¬Lec PFÓë×ÜtauºÍÉñ¾­¿ÅÁ£ÂѰף¨A¦Â¼¶ÁªÖÐA¦ÂÏÂÓεÄÉñ¾­ÍËÐÐÐÔ±ê¼ÇÎÌåÏÖ³öºÜÇ¿µÄÏà¹ØÐÔ£¨SpearmanϵÊýΪ0.4»ò¸ü¸ß£©£¬ÕâÊÇADµÄ²¡Àíѧ¸Ä±ä£¬±êÃ÷Lec PFÊÇÒ»ÖÖÓëÉñ¾­ÍËÐÐÐÔ¼²²¡Ïà¹ØµÄ¾ç¶¾²¡ÀíÂѰס£

δÀ´Éú³¤

ÔÚÂØ¿¨Ä¹ÖÎÁÆÇ°ºóÕÉÁ¿CSFÖеÄLec-PFŨ¶È¿ÉÄÜÓÐÖúÓÚÆÀ¹ÀÂØ¿¨Ä¹ÖÎÁƵÄÁÆÐ§¡£±ðµÄ£¬ÓÉÓÚCSFÖÐLec-PFµÄŨ¶ÈÓëÉñ¾­ÍËÐÐÐÔ±ê¼ÇÎïÃÜÇÐÏà¹Ø£¬Òò´ËËüÒ²¿ÉÄÜÓÐÖúÓÚÔ¤²âAD»¼ÕßµÄÔ¤ºó¡£

±¾Ñо¿»ñµÃÁËÈÕ±¾Ò½Ñ§Ñо¿¿ª·¢»ú¹¹£¨AMED£©³Õ´ôÖ¢Ñо¿ÓëÉú³¤×ÊÖú£¨×ÊÖúºÅ22dk0207053£©¡¢×ªÐÍÑо¿×ÊÖú£¨×ÊÖú±àºÅ23H03850£©ºÍ¿ÆÑ§Ñо¿×ÊÖú£¨Åú×¼ºÅJP19k07965¡¢JP22k07514£©µÈÏîÄ¿µÄÖ§³Ö¡£

ͼ 1 ƾ¾ÝÁÙ´²Õï¶ÏºÍµí·ÛÑùÂѰ×ÑôÐÔ/ÒõÐÔ·ÖÀàµÄÄÔ¼¹ÒºÂØ¿¨Ä¹Ïà¹Øµí·ÛÑùÂѰ×Ô­ÏËά£¨CSF Lec-PF£©Å¨¶È

ÄϹ¬NG28(Öйú)¹Ù·½ÍøÕ¾-µÇ¼Èë¿Ú

ͼ 1 ˵Ã÷

·½¿òͼÖеķ½¿òÌåÏÖËÄ·ÖλÊý¼ä¾à£¬Ë®Æ½ÏßÌåÏÖÖÐλÊý¡£¸÷×éËõд£º YNC£¨ÄêÇáÕý³£±ÈÕÕ×éµí·ÛÑùÂѰ×ÒõÐÔ£©¡¢AMC£¨ÄêÁ䯥Åä±ÈÕÕ×éµí·ÛÑùÂѰ×ÒõÐÔ£©¡¢CI-£¨ÈÏÖª¹¦Ð§ÊÜËð×éµí·ÛÑùÂѰ×ÒõÐÔ£©¡¢CU+£¨ÈÏÖª¹¦Ð§Î´ÊÜËð×éµí·ÛÑùÂѰ×ÑôÐÔ£©¡¢MCI+£¨Çá¶ÈÈÏÖª¹¦Ð§ÊÜËð×éµí·ÛÑùÂѰ×ÑôÐÔ£©¡¢AD+£¨AD ³Õ´ô×éµí·ÛÑùÂѰ×ÑôÐÔ£©¡¢CSF£¨ÄÔ¼¹Òº£©¡£

*p < 0.05

ͼ 2 ÄÔ¼¹Òº±ê¼ÇÎïÓëÄÔ¼¹ÒºÂØ¿¨Ä¹Ïà¹Øµí·ÛÑùÂѰ×Ô­ÏËά£¨CSF Lec-PF£©µÄÏà¹ØÐÔ

ÄϹ¬NG28(Öйú)¹Ù·½ÍøÕ¾-µÇ¼Èë¿Ú

ͼ2˵Ã÷

ºÚÏߺͺìÏß»®·ÖÌåÏÖÕû¸öÊÜÊÔÕß×éºÍµí·ÛÑùÂѰ×ÑôÐÔÊÜÊÔÕß×éCSF Lec-PFÓë¸÷ÄÔ¼¹Òº±ê¼ÇÎïÖ®¼ä˹Ƥ¶ûÂüÏà¹ØÏµÊýµÄ95%ÖÃÐÅÇø¼ä (CI)¡£ºÚµãºÍºìµãÌåÏÖ˹Ƥ¶ûÂüÏà¹ØÏµÊýµÄÖÐÖµ¡£ºÚÏߺͺìÏßÖ®¼äµÄ¾Þ´ó²î±ð·´Ó¦ÁËA¦Â ÑôÐÔ»òÒõÐÔ״̬µÄÏÔÖøÓ°Ïì¡£

ÔÚÕâÏîÆÊÎöÖУ¬ËùÓÐÊÜÊÔÕߣ¨ºÚÏߣ©µÄCSF Lec-PFÓëËùÓвⶨµÄÉúÎï±ê¼ÇÎ¼´A¦Â42¡¢A¦Â42/40±ÈÖµ¡¢p-tau 181¡¢p-tau 217¡¢×Ü-tauºÍÉñ¾­¿ÅÁ£ÂѰף©Ö®¼äµÄÏà¹ØÏµÊý¾ùΪ0.2»ò¸ü¸ß£¬±êÃ÷ CSF Lec-PF ÓëÕâЩÉúÎï±ê¼ÇÎïÖ®¼ä±£´æÏÔÖøÏà¹ØÐÔ¡£ÔÚµí·ÛÑùÂѰ×ÑôÐÔ×飨ºìÏߣ©ÖУ¬CSF Lec-PFÓëCSF total-tauµÄSpearmanÏà¹ØÏµÊý»®·ÖΪ0.634£¨CI£º0.409-0.786£©£¬CSF Lec-PFÓëCSF neurograninµÄSpearmanÏà¹ØÏµÊý»®·ÖΪ0.434£¨CI£º0.260-0.581£©£¬±êÃ÷CSF Lec-PFÓëÕâÁ½ÖÖÉúÎï±ê¼ÇÎïÖ®¼ä±£´æºÜÇ¿µÄÏà¹ØÐÔ¡£ÁíÒ»·½Ã棬CSF Lec-PFÓëÄÔA¦ÂÀÛ»ýÉúÎï±ê¼ÇÎïCSF A¦Â42ºÍCSF A¦Â42/40±ÈÖµÖ®¼äµÄÏà¹ØÐÔ¶¼Ïà¶Ô½ÏµÍ¡£Õâ±êÃ÷£¬CSF Lec-PFµÄº¬Á¿ÓëÉñ¾­ÍËÐÐÐÔ±äµÄ¹ØÏµ±È´óÄÔÖÐA¦ÂµÄ»ýÀÛ¸üΪÃÜÇС£

 

ÎÄÕ·¢ÐÄÇé¿ö£º

ÆÚ¿¯Ãû³Æ£ºAnnals of Neurology

ÎÄÕÂÌâÄ¿: Lecanemab-associated amyloid-¦Â protofibril in cerebrospinal fluid correlates with

biomarkers of neurodegeneration in Alzheimer¡¯s disease (Cerebrospinal fluid (CSF) lecanemab-associated amyloid protofibril concentrations correlate well with neurodegenerative biomarkers in AD)

×÷Õß: Moeko Noguchi-Shinohara, Kazuyoshi Shuta, Hidetomo Murakami, Yukiko Mori, Junji Komatsu, Chizuru Kobayashi, Steven Hersch, Kanta Horie, Kenjiro Ono

Ðû²¼ÈÕÆÚ£ºJanuary 6, 2025 (US Eastern Standard Time).

DOI: 10.1002/ANA.27175

 

ÐÅÏ¢ÁªÂ磺

¡ö Regarding research content

Kanazawa University

Professor Kenjiro Ono

TEL: +81-(0)76-265-2292

Email: onoken@med.kanazawa-u.ac.jp

Associate Professor Moeko Shinohara

TEL: +81-(0)76-265-2292

Email: m-nohara@med.kanazawa-u.ac.jp

Eisai Co., Ltd.

Kanta Horie

E-mail: kanta_horie@eisai.com

¡ö Public Relations Officer

General Affairs Section, General Affairs Division, Medical, Pharmaceutical and Health Sciences

Administration Department, Kanazawa University

Rina Yamada

TEL: +81-(0)76-265-2109

E-mail: t-isomu@adm.kanazawa-u.ac.jp

Eisai Co., Ltd. PR Department

TEL: +81-(0)3-3817-5120

±àºÅ£ºECN2025-0002

ÍøÕ¾µØÍ¼